Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Inhibition of p21-Activated Kinase (PAK) as a new molecular target in the treatment of chronic myeloid leukemia (CML)

2013/11/B/NZ7/02248

Keywords:

chronic myeloid leukemia (CML) tyrosine kinase inhibitors (TKI) PAK inhibitor apoptosis ROS

Descriptors:

  • NZ7_14: Pharmacy, pharmacotherapy, pharmacology

Panel:

NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology

Host institution :

Narodowy Instytut Leków

woj. mazowieckie

Other projects carried out by the institution 

Principal investigator (from the host institution):

dr hab. Sylwia Flis 

Number of co-investigators in the project: 5

Call: OPUS 6 - announced on 2013-09-16

Amount awarded: 638 828 PLN

Project start date (Y-m-d): 2014-09-10

Project end date (Y-m-d): 2019-09-09

Project duration:: 60 months (the same as in the proposal)

Project status: Project settled

Equipment purchased [PL]

  1. cytometr przepływowy BD Accuri C6 (250 000 PLN)

Information in the final report

  • Publication in academic press/journals (3)
  • Articles in post-conference publications (3)
  1. Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells.
    Authors:
    Flis S, Bratek E, Chojnacki T, Piskorek M, Skorski T
    Academic press:
    Cancers (Basel) (rok: 2019, tom: 11(10), strony: 16), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/cancers11101544. - link to the publication
  2. Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities
    Authors:
    Sylwia Flis, Tomasz Chojnacki
    Academic press:
    Drug Design, Development and Therapy (rok: 2019, tom: 13, strony: 19), Wydawca: Dovepress
    Status:
    Published
    DOI:
    10.2147/DDDT.S191303 - link to the publication
  3. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms
    Authors:
    Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, Wasik M, Koschmieder S, Green TR, Skoda RC, Skorski T.
    Academic press:
    Blood (rok: 2017, tom: 130(26), strony: 2848-2859), Wydawca: American Society of Hematology
    Status:
    Published
    DOI:
    10.1182/blood-2017-05-784942 - link to the publication
  1. Inhibition of PAK1/2 kinases enhance imatinib mechanism of action in eradication of CML stem cells
    Authors:
    Flis S, Chojnacki T, Skorski T
    Conference:
    The 44th FEBS Congress (rok: 2019, ), Wydawca: PCO&DMC Krakow
    Data:
    konferencja 6-11.07.2019
    Status:
    Published
    DOI:
    link to the publication
  2. Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinases Exerts Synergistic Effect Against Chronic Myeloid Leukemia (CML) Cells
    Authors:
    Flis S, Chojnacki T, Bratek E, Skorsk Ti
    Conference:
    21st Annual John Goldman Conference on Chronic Myeloid Leukemia (rok: 2019, ), Wydawca: EAH
    Data:
    konferencja 12-15.09.2019
    Status:
    Published
  3. PAK1 and PAK2 kinases are possible molecular therapeutic targets in the CML
    Authors:
    Flis S, Bratek E, Chojnacki T.
    Conference:
    Genes and Cancer 2017 Meeting (rok: 2017, ), Wydawca: In Conference Ltd
    Data:
    konferencja 10-12.04.2017
    Status:
    Published

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy